Visus Therapeutics Inc.

https://www.visustx.com

LinkedIn: https://www.linkedin.com/company/visus-therapeutics

Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates. *

	Start	2020-09-28 start announced
	Industry	ophthalmic
	Industry 2	drug development

	Street	2 Nickerson Street Suite 101
	City	98109 Seattle, WA
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Visus Therapeutics Inc.

[1] Visus Therapeutics Inc.. (8/10/21). "Press Release: Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners". Seattle, WA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)